Back to Resource Center

New HIV prevention approaches: promise, praxis, and pitfalls

More than a decade since the demonstration that antiretrovirals used for pre-exposure prophylaxis (PrEP) were safe and effective in decreasing HIV transmission, these medications remain underused, but continue to be needed, given the persistent burden of incident HIV infection, particularly in multiple sub-Saharan African countries. In 2020, there were about 1·5 million new HIV infections globally, representing a decline of only 31% since 2010. Oral tenofovir-based PrEP is highly effective, but disparities remain due to lower PrEP uptake and adherence among populations disproportionately impacted by HIV. Less than a third of approximately 3 million people who could benefit from PrEP have used it, with most PrEP users located in affluent countries.

July 2023

Click for full info +

Full Info:


Resource Type:

Database
Journal Article
Journal Article
Resource

Citation:

More than a decade since the demonstration that antiretrovirals used for pre-exposure prophylaxis (PrEP) were safe and effective in decreasing HIV transmission, these medications remain underused, but continue to be needed, given the persistent burden of incident HIV infection, particularly in multiple sub-Saharan African countries. In 2020, there were about 1·5 million new HIV infections globally, representing a decline of only 31% since 2010. Oral tenofovir-based PrEP is highly effective, but disparities remain due to lower PrEP uptake and adherence among populations disproportionately impacted by HIV. Less than a third of approximately 3 million people who could benefit from PrEP have used it, with most PrEP users located in affluent countries.

View Journal Article

Authors: Mayer, K.H., Phanuphak, N., Mgodi, N. and Grinsztejn, B.

Health Risks(s):

  • HIV

Product type(s):

  • HIVinhibitor
  • Other

Topic(s):

  • Product Introduction

Region(s)

  • Africa

Back to Resource Center